Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 5:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,348 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SARS CoV-2 Infection Clear all
Withdrawn Phase 4 Interventional

Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial

NCT04382625
View directory record Official record
Conditions
SARS-CoV-2 Pneumonia, COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Kootenai Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Coeur d'Alene, Idaho
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 14, 2026, 5:11 PM EDT
Completed No phase listed Observational

A Clinical Evaluation of Proof Diagnostics Test System Including the Proof Diagnostics Reader and COVID-19 Test

NCT05331976
View directory record Official record
Conditions
COVID-19, Asymptomatic COVID-19
Interventions
Proof Lab Test System
Diagnostic Test
Lead sponsor
Proof Diagnostics
Industry
Eligibility
2 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Spring Hill, Florida • Statesville, North Carolina • Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 14, 2026, 5:11 PM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin in Respiratory Failure in Patients With COVID-19

NCT04350593
View directory record Official record
Conditions
COVID-19
Interventions
Dapagliflozin 10 milligram (mg), Placebo
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
22
States / cities
Fairhope, Alabama • Miami, Florida • Evanston, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Sep 14, 2026, 5:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays

NCT04562285
View directory record Official record
Conditions
Covid19
Interventions
Serologic immunoassays to SARS-CoV-2 antibodies
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 14, 2026, 5:11 PM EDT
Completed Phase 3 Interventional Results available

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

NCT04401293
View directory record Official record
Conditions
Sars-CoV2, COVID
Interventions
Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 14, 2026, 5:11 PM EDT
Completed No phase listed Observational

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib

NCT05594147
View directory record Official record
Conditions
Malignant Solid Tumors, Coronavirus Disease 2019 (COVID-19), SARS-CoV-2 Infection
Interventions
Non-TKIs, Other TKIs, Regorafenib (Stivarga, BAY73- 4506), Sorafenib (Nexavar, BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 14, 2026, 5:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial

NCT04847349
View directory record Official record
Conditions
Covid19
Interventions
OL-1, standard dose, OL-1, high dose, Placebo
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 14, 2026, 5:11 PM EDT
Terminated Phase 1 Interventional Results available

Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)

NCT05027815
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Interventions
Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
Biological
Lead sponsor
Jeffrey Bluestone
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 14, 2026, 5:11 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Restoring Non-Emergent Cardiovascular Care in the Peri- COVID-19 Era

NCT04636021
View directory record Official record
Conditions
Corona Virus Infection
Interventions
COVID-19 testing
Diagnostic Test
Lead sponsor
Pinnacle Health Cardiovascular Institute
Network
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Harrisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 14, 2026, 5:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic

NCT04459455
View directory record Official record
Conditions
Anxiety
Interventions
Contain COVID Anxiety SSI, Remain COVID Free SSI
Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 14, 2026, 5:11 PM EDT
Withdrawn Phase 1 Interventional

Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias

NCT05286255
View directory record Official record
Conditions
COVID-19 Pneumonia, Viral Pneumonia
Interventions
Allogeneic Mesenchymal Stromal Cells
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 14, 2026, 5:11 PM EDT
Terminated No phase listed Observational

Compensatory Reserve Index (CRI) for Management of COVID-19

NCT04457817
View directory record Official record
Conditions
COVID
Interventions
CRI
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 14, 2026, 5:11 PM EDT
Completed Phase 2 Interventional Results available

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

NCT04583592
View directory record Official record
Conditions
COVID-19
Interventions
Camostat Mesilate, Placebo
Drug
Lead sponsor
Sagent Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Palm Springs, California • Bradenton, Florida • Brandon, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 14, 2026, 5:11 PM EDT
Terminated Phase 4 Interventional

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

NCT04505098
View directory record Official record
Conditions
Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections
Interventions
Icosapent ethyl
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years and older
Enrollment
39,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 14, 2026, 5:11 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants

NCT04914377
View directory record Official record
Conditions
Covid19
Interventions
TQ Formula/Tab
Drug
Lead sponsor
Novatek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
San Diego, California • Hialeah, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Sep 14, 2026, 5:11 PM EDT
Completed No phase listed Observational

COVID EHR COHORT at the University of Wisconsin

NCT04506528
View directory record Official record
Conditions
COVID-19, Cancer, Nicotine Dependence, Pulmonary Disease, Cardiovascular Diseases, Immunosuppression Disorders
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
0 Years and older
Enrollment
1,634,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Sep 14, 2026, 5:11 PM EDT
Terminated Phase 2 Interventional Results available

PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19

NCT05543707
View directory record Official record
Conditions
COVID-19
Interventions
PBI-0451 (Pomotrelvir), Placebo
Drug
Lead sponsor
Pardes Biosciences, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
54
States / cities
Mesa, Arizona • Bakersfield, California • Canoga Park, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 14, 2026, 5:11 PM EDT
Completed Not applicable Interventional Results available

UVA Light Device to Treat COVID-19

NCT04572399
View directory record Official record
Conditions
Coronavirus
Interventions
UV Light Treatment
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 14, 2026, 5:11 PM EDT
Completed No phase listed Observational

Cardiopulmonary Exercise Tests in Patients With Long COVID

NCT06394921
View directory record Official record
Conditions
Long COVID, COVID Long-Haul
Interventions
2 day cardiopulmonary exercise test
Procedure
Lead sponsor
Sheffield Hallam University
Other
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 14, 2026, 5:11 PM EDT
Recruiting Phase 2 Interventional

Arginine Replacement Therapy in COVID-19

NCT05855330
View directory record Official record
Conditions
COVID-19
Interventions
Arginine Hydrochloride
Drug
Lead sponsor
Emory University
Other
Eligibility
3 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 14, 2026, 5:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

COVID-19 Responsive Intervention: Systems Improvement Simulations (CRI:SIS)

NCT04614844
View directory record Official record
Conditions
Physician Stress Levels
Interventions
Simulation Intervention, Control
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 14, 2026, 5:11 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Promoting the Well Being of Caregivers Via Telehealth

NCT05999448
View directory record Official record
Conditions
Caregivers, Parents
Interventions
Acceptance and Commitment Therapy (ACT), Culturally Informed Cognitive Behavioral Therapy (CICBT), Individual, Culturally Informed Cognitive Behavioral Therapy (CICBT), Group, Dialectical Behavioral Therapy (DBT), Durand Sleep Intervention, RUBI Intervention, Naturalistic Communication Intervention (NCI), Self-Guided Resources, Participation Enhancement Intervention (PEI)
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 70 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 14, 2026, 5:11 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

NCT06178991
View directory record Official record
Conditions
Influenza, COVID-19
Interventions
Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 64 Years
Enrollment
8,795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
106
States / cities
Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 14, 2026, 5:11 PM EDT
Completed Not applicable Interventional

Improving Attention in Individuals With Long COVID-19

NCT06503874
View directory record Official record
Conditions
Long Covid
Interventions
Attention Training, Music Group
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 14, 2026, 5:11 PM EDT